Triple Drug Combo for Advanced Breast Cancer Hits Targets but Falls Short of Standard Care
A phase Ib/II trial testing famitinib added to dalpiciclib and fulvestrant in HR-positive, HER2-negative advanced breast cancer met early response ...
A phase Ib/II trial testing famitinib added to dalpiciclib and fulvestrant in HR-positive, HER2-negative advanced breast cancer met early response ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine